Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Otsuka Pharmaceutical Development & Commercialization, Inc. appears in 155 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials155
Recruiting shown1
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the BodyNCT07525960 · lead sponsor · 2026-07-07
RECRUITING
A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the BodyNCT07649265 · lead sponsor · 2026-09-15
NOT_YET_RECRUITING
A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male AdultsNCT07455084 · lead sponsor · 2026-03-20
NOT_YET_RECRUITING
A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart FailureNCT06795399 · lead sponsor · 2025-04-30
WITHDRAWN
A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and WomenNCT07305779 · lead sponsor · 2025-03-07
COMPLETED
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaNCT06894212 · lead sponsor · 2025-02-28
ACTIVE_NOT_RECRUITING
A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive EpisodeNCT07549581 · lead sponsor · 2024-11-07
COMPLETED
A Trial to Assess a Wearable Patch's Functioning to Detect Medication IngestionNCT06372210 · lead sponsor · 2023-06-26
COMPLETED
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With SchizophreniaNCT05848700 · lead sponsor · 2023-06-21
COMPLETED
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic MedicationNCT05741528 · lead sponsor · 2023-03-31
COMPLETED
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic MedicationNCT05628103 · lead sponsor · 2022-12-19
COMPLETED
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With SchizophreniaNCT05542264 · lead sponsor · 2022-11-15
COMPLETED
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive DisorderNCT05593029 · lead sponsor · 2022-11-09
COMPLETED
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive DisorderNCT05536414 · lead sponsor · 2022-09-12
COMPLETED
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/SertralineNCT05189977 · lead sponsor · 2022-09-07
TERMINATED
A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With SchizophreniaNCT05463770 · lead sponsor · 2022-08-30
COMPLETED
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and AnxietyNCT05504486 · lead sponsor · 2022-08-29
WITHDRAWN
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) StandardNCT05402111 · lead sponsor · 2022-06-13
COMPLETED
A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.NCT04865835 · lead sponsor · 2021-05-12
COMPLETED
Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive DisorderNCT04830215 · lead sponsor · 2021-04-01
COMPLETED
Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive DisorderNCT04770285 · lead sponsor · 2021-02-25
COMPLETED
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT04464564 · lead sponsor · 2020-09-11
TERMINATED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT04408755 · lead sponsor · 2020-07-13
TERMINATED
A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.NCT04369391 · lead sponsor · 2020-06-18
COMPLETED
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.NCT04115319 · lead sponsor · 2019-11-21
COMPLETED
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With SchizophreniaNCT04109950 · lead sponsor · 2019-11-20
TERMINATED
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaNCT04092686 · lead sponsor · 2019-10-14
COMPLETED
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaNCT04072354 · lead sponsor · 2019-09-17
COMPLETED
A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) ImagingNCT04038957 · lead sponsor · 2019-08-07
COMPLETED
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 DisorderNCT04030143 · lead sponsor · 2019-08-01
COMPLETED
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®NCT03892889 · lead sponsor · 2019-04-29
TERMINATED
Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar DisorderNCT03872596 · lead sponsor · 2019-03-27
COMPLETED
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of SchizophreniaNCT03896945 · lead sponsor · 2019-02-15
TERMINATED
A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I DisorderNCT03854409 · lead sponsor · 2019-01-31
COMPLETED
A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's TypeNCT03594123 · lead sponsor · 2018-10-11
COMPLETED
A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive DisorderNCT03538691 · lead sponsor · 2018-07-13
COMPLETED
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive DisorderNCT03643159 · lead sponsor · 2018-06-28
TERMINATED
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical AntipsychoticNCT03568500 · lead sponsor · 2018-05-21
COMPLETED
A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's TypeNCT03548584 · lead sponsor · 2018-05-16
COMPLETED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT03393520 · lead sponsor · 2017-10-13
COMPLETED
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With SchizophreniaNCT03238326 · lead sponsor · 2017-08-23
COMPLETED
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With SchizophreniaNCT03198078 · lead sponsor · 2017-06-30
COMPLETED
Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With SchizophreniaNCT03150771 · lead sponsor · 2017-06-14
COMPLETED
An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With SchizophreniaNCT02970929 · lead sponsor · 2017-01-31
COMPLETED
Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With SchizophreniaNCT02968121 · lead sponsor · 2017-01-01
TERMINATED
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease PsychosisNCT02969369 · lead sponsor · 2016-12-31
COMPLETED
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With SchizophreniaNCT02969382 · lead sponsor · 2016-12-05
COMPLETED
Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine SystemNCT02722967 · lead sponsor · 2016-03-01
COMPLETED
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT02446132 · lead sponsor · 2015-11-13
TERMINATED
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's TypeNCT02442778 · lead sponsor · 2015-11-11
COMPLETED
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual SchizophreniaNCT02477670 · lead sponsor · 2015-09-01
COMPLETED
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT02442765 · lead sponsor · 2015-07-23
COMPLETED
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With SchizophreniaNCT02411695 · lead sponsor · 2015-03-01
COMPLETED
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With ImpulsivityNCT02194933 · lead sponsor · 2015-02-01
COMPLETED
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and IrritabilityNCT02212613 · lead sponsor · 2014-09-01
WITHDRAWN
Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral AripiprazoleNCT02219009 · lead sponsor · 2014-08-01
COMPLETED
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious DistressNCT02196506 · lead sponsor · 2014-07-01
COMPLETED
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentNCT02153502 · lead sponsor · 2014-07-01
COMPLETED
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or PlaceboNCT02192554 · lead sponsor · 2014-06-01
COMPLETED
Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype CharacteristicsNCT01972711 · lead sponsor · 2014-03-01
COMPLETED

Drugs studied in this sponsor's trials

20 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Otsuka Pharmaceutical Development & Commercialization, Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo43
aripiprazole40
brexpiprazole16
tolvaptan7
escitalopram6
olanzapine2
amisulpride1
aripiprazole Oral Tablet1
placebo RxCUI 8375 · Lead sponsor in 40 linked trial(s) · 2 currently recruiting 43 trials aripiprazole RxCUI 89013 · Lead sponsor in 40 linked trial(s) · 0 currently recruiting 40 trials brexpiprazole RxCUI 1658314 · Lead sponsor in 16 linked trial(s) · 0 currently recruiting 16 trials tolvaptan RxCUI 358257 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 7 trials escitalopram RxCUI 321988 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 6 trials olanzapine RxCUI 61381 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials amisulpride RxCUI 46303 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial aripiprazole Oral Tablet RxCUI 378301 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial duloxetine RxCUI 72625 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial fluoxetine RxCUI 4493 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial metformin RxCUI 6809 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial moxifloxacin RxCUI 139462 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial moxifloxacin 400 MG RxCUI 330383 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial placebo Oral Tablet RxCUI 375221 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial prazosin RxCUI 8629 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial propranolol RxCUI 8787 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial quetiapine RxCUI 51272 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial quinidine gluconate RxCUI 35220 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial risperidone RxCUI 35636 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial sertraline RxCUI 36437 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor150
collaborator5
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.